A couple morsels on this topic from Fine and Fierce Biotech today.
Fine reported that ScinoPharm (Taiwan) invested in Tanvex Biologics to enter the CMO market for biologics in the US. Tanvex is involved with biosimilars, biobetters and does contract research and manufacturing for biologics. Tanvex is establishing a cGMP facility in San Diego, CA. It will have research centers in CA and Taiwan.
Fierce Biotech reports that Actavis (Iceland) has acquired a 51 percent stake in Poland's Bioton. Bioton gives Actavis an entrance to the biosimilar market too. Actavis is shifting toward biosimilars as a new growth area and notes some analysts project that this market will reach $10 B by 2015.
Posted by Bruce Lehr September 7th 2010.
Comments